RUC. Repositorio da Universidade da Coruña
Publication
Artículo científico (JournalArticle)
Empiric therapy with Carbapenem-sparing regimens for bloodstream infections due to extended-spectrum β-Lactamase–producing Enterobacteriaceae: results from the INCREMENT cohort
[Abstract] Background: There is little information about the efficacy of active alternative drugs to carbapenems except β-lactam/β-lactamase inhibitors for the treatment of bloodstream infections (BSIs) due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E). The objective of this study was to assess the outcomes of patients with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or carbapenems.
Methods: A multinational retrospective cohort study of patients with BSI due to ESBL-E who received empiric treatment with OADs or carbapenems was performed. Cox regression including a propensity score for receiving OADs was performed to analyze 30-day all-cause mortality as main outcome. Clinical failure and length of stay were also analyzed.
Results: Overall, 335 patients were included; 249 received empiric carbapenems and 86 OADs. The most frequent OADs were aminoglycosides (43 patients) and fluoroquinolones (20 patients). Empiric therapy with OADs was not associated with mortality (hazard ratio [HR], 0.75; 95% confidence interval [CI], .38-1.48) in the Cox regression analysis. Propensity score-matched pairs, subgroups, and sensitivity analyses did not show different trends; specifically, the adjusted HR for aminoglycosides was 1.05 (95% CI, .51-2.16). OADs were neither associated with 14-day clinical failure (adjusted odds ratio, 0.62; 95% CI, .29-1.36) nor length of hospital stay.
Conclusions: We were unable to show that empiric treatment with OAD was associated with a worse outcome compared with carbapenems. This information allows more options to be considered for empiric therapy, at least for some patients, depending on local susceptibility patterns of ESBL-E., The study was funded by the Ministerio de Economía y Competitividad-Instituto de Salud Carlos III through the following grants: Acción Estratégica en Salud (PI10/02021 and PI14/01832), and Plan Nacional de I+D+i, Subdirección General de Redes y Centros de Investigación Cooperativa, Spanish Network for Research in Infectious Diseases (REIPI RD 12/0015/0010 and RD16/0016/0001), co-financed by the European Development Regional Fund “A way to achieve Europe,” Operative Programme Intelligent Growth 2014–2020. B. G. G., J. R. B., A. P. H., and Y. C. also received funds from the Innovative Medicines Initiative, the European Union’s Seventh Framework Programme (FP7/2007–2013), and in-kind contributions from European Federation of Pharmaceutical Industries and Associations companies (COMBACTE-CARE project, agreement 115620). R. A. B. was also supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program and the Geriatric Research Education and Clinical Center VISN 10 (VISN 10 GRECC), and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award numbers R01AI072219 and R01AI063517.
Project:
MINECO / FP7 PI14-01832
,
EC 115620
View at: https://hdl.handle.net/2183/48060